Three-month Eligard product receives marketing authorisation in Germany

Published: 26-Jan-2004

MediGene, the European licensee of US-based Atrix Laboratories, has received marketing authorisation from the German pharmaceutical regulatory authority, Bundesinstitut fuer Arzneimittel und Medizinprodukte (BfArM), for the company's three-month prostate cancer product, Eligard 22.5mg (leuprolide acetate for injectable suspension).


MediGene, the European licensee of US-based Atrix Laboratories, has received marketing authorisation from the German pharmaceutical regulatory authority, Bundesinstitut fuer Arzneimittel und Medizinprodukte (BfArM), for the company's three-month prostate cancer product, Eligard 22.5mg (leuprolide acetate for injectable suspension).

Recently, the company announced that Yamanouchi would be the pan-European sales and marketing licensee for the Eligard product line.

'This approval comes approximately a month after the Eligard 7.5mg once-a-month prostate cancer product received marketing authorisation in Germany,' said David R. Bethune, Atrix's chairman and ceo. 'With this second approval, Eligard is now well positioned to compete in this large LHRH prostate cancer market.'

  

You may also like